Clinical Trials Logo

Vaginosis, Bacterial clinical trials

View clinical trials related to Vaginosis, Bacterial.

Filter by:

NCT ID: NCT03099408 Completed - Recurrence Clinical Trials

Oral Metronidazole With Lactobacillus Vaginal Suppositories to Prevent Recurrence of Bacterial Vaginosis

Start date: July 1, 2017
Phase: Phase 4
Study type: Interventional

We are trying to determine if Oral Metronidazole with Lactobacillus Vaginal Suppositories is better than Oral Metronidazole in Preventing the Recurrence of Bacterial Vaginosis

NCT ID: NCT03091777 Completed - Bacterial Vaginosis Clinical Trials

Study Evaluating the Equivalence of GDC-229 and Metronidazole Vaginal Gel 0.75% in the Treatment of Bacterial Vaginosis

Start date: March 10, 2017
Phase: Phase 3
Study type: Interventional

This research study is being done to compare the safety and efficacy of GDC-229 (test drug) against the currently marketed reference drug (metronidazole 0.75% vaginal gel) and to establish that these two drugs work better than placebo in subjects with BV.

NCT ID: NCT03080740 Recruiting - Bacterial Vaginosis Clinical Trials

The Efficacy and Safety Study of Clindamycin Palmitate Hydrochloride Dispersible Tablet Treatment of Bacterial Vaginosis

Start date: July 2016
Phase: Phase 4
Study type: Interventional

Randomized, double blind, positive drug parallel comparison, multi-centre clinical trial to assess the Efficacy and Safety of Clindamycin palmitate hydrochloride dispersible tablet for the treatment of bacterial vaginosis

NCT ID: NCT03045809 Completed - Clinical trials for Urinary Tract Infections

Women's Improvement of Sexual Health (WISH) Demonstration Project

WISH
Start date: July 5, 2016
Phase:
Study type: Observational

The current standard of care for urogenital infections in Rwanda is syndromic management. Many urogenital infections are asymptomatic and therefore completely missed, and the management of vaginal discharge syndrome is known to be suboptimal. The primary objective of this study is to evaluate whether it is feasible to improve urogenital infection care in high risk women in Kigali, Rwanda, using point of care (POC) diagnostic testing for HIV, Trichomonas vaginalis (TV), and bacterial vaginosis (BV) in all women; POC testing for Neisseria gonorrhoeae (NG), Chlamydia trachomatis (CT), and syphilis in pregnant women and women assessed to be at high risk for these infections using a risk scoring questionnaire; and management of vaginal candidiasis, urinary tract infection (UTI), genital ulcers/inguinal bubos, and lower abdominal pain in women reporting relevant symptoms. The secondary objectives of this study are 1) to evaluate the performance and 2) to obtain the opinions of Rwandan stakeholders.

NCT ID: NCT02946346 Terminated - Bacterial Vaginosis Clinical Trials

Kinetics and Ecology of Human Papillomavirus Genital Infections in Young Women

PAPCLEAR
Start date: November 11, 2016
Phase: N/A
Study type: Interventional

Most genital infections by human papillomaviruses (HPV) are asymptomatic or benign and clear within a few months or years. There infections are much less studies than chronic infections, even though they represent the main reservoir for the virus. The goal of this project is to decipher the kinetics of the virus and of the host immune response in acute HPV genital infections in your women. This will be performed by following women longitudinally and regularly in order to measure variations in virus load, immune cell count, cytokine concentration and antibody titers. The investigators will also investigate the interaction between these kinetics and host genetics and host vaginal microbiota

NCT ID: NCT02905890 Completed - HIV Clinical Trials

The Effect of Norethisterone Enanthate on Recurrent Bacterial Vaginosis

HCBV
Start date: October 2, 2017
Phase: Phase 4
Study type: Interventional

The proposed study, Hormonal Contraception & BV (HCBV), will investigate the effect of NET-EN and DMPA on recurrent BV, vaginal microbiota and inflammatory markers among women at high risk for HIV in Kampala, Uganda. The hypothesis is that NET-EN will show a similar beneficial effect on recurrent BV and vaginal microbiota as DMPA, without inducing signs of mucosal inflammation.

NCT ID: NCT02866227 Completed - Bacterial Vaginosis Clinical Trials

TOL-463 Phase 2 Study for Vaginitis

Start date: July 15, 2016
Phase: Phase 2
Study type: Interventional

This is a Phase II study designed to assess the safety and efficacy of an investigational product, TOL-463, to treat vaginitis.

NCT ID: NCT02863536 Completed - Bacterial Vaginosis Clinical Trials

A Study of the New Medical Device Polybactum®

POLARIS
Start date: September 8, 2016
Phase: N/A
Study type: Interventional

The POLARIS trial is designed as a multicenter, open label, non-comparative, 3 months, clinical study. Interventional, non-controlled, multicenter trial with a prospective design on one cohort of patients

NCT ID: NCT02860845 Completed - Candidiasis Clinical Trials

Use of Boric Acid in Combination With Probiotics for the Treatment of Vaginal Infections

DOBO
Start date: July 12, 2016
Phase: Phase 4
Study type: Interventional

The purpose of this study is to determine whether a formula of boric acid and probiotics for vaginal application is effective in the treatment of symptomatic episodes of vulvovaginitis in comparison to pharmacological reference controls (depending on the suspected diagnosis).

NCT ID: NCT02795845 Completed - Clinical trials for Bacterial Vaginosis and Vaginal Candidiasis at Pregnancy

Oral Probiotics for the Treatment and Prevention of Vulvovaginal Infections in Pregnancy - Double-blind, Randomized, Placebo-controlled Study

Start date: November 2016
Phase: N/A
Study type: Interventional

During pregnancy, bacterial vaginosis (BV), abnormal vaginal flora (AVF) and vulvovaginal candidiasis (VVC) are associated with serious complications and discomfort. Yet, treatment options are limited. Lactobacilli administration was suggested to treat and prevent vaginal infections. However, this has not been examined in pregnant women, the information regarding oral treatment is scarce, and the mechanisms in which oral ingestion of probiotics induce vaginal lactobacilli proliferation are not well established. In the present study we will examine if oral probiotics are effective in prevention of vaginal infections by migration of lactobacilli from the digestive system to the vagina in pregnant women.